SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is experiencing extreme volatility as market participants react to increased margin requirements on silver futures and looming export restrictions from China. Bulls are confident in a significant run-up, citing growing industrial demand and perceived market manipulation, while bears warn of an unsustainable "pump and dump" destined for a sharp correction. The community remains fiercely divided, reflecting intense debate over the metal's true value and trajectory.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies (BMNR) is actively trending as it commences staking its significant Ethereum holdings, a move viewed by many as a key step toward generating substantial future revenue. However, community discussions are sharply divided over ongoing concerns about share dilution below net asset value and proposed executive compensation, with critics highlighting the stock's notable underperformance compared to Ethereum's price. Investors are closely watching the upcoming shareholder meeting for clarity on strategic direction amidst year-end market dynamics affecting valuation.

The Stellar network is an open source, distributed, and community owned network used to facilitate cross-asset transfers of value. Stellar aims to help facilitate cross-asset transfer of value at a fraction of a penny while aiming to be an open financial system that gives people of all income levels access to low-cost financial services. Stellar can handle exchanges between fiat-based currencies and between cryptocurrencies. Stellar.org, the organization that supports Stellar, is centralized like XRP and meant to handle cross platform transactions and micro transactions like XRP. However, unlike Ripple, Stellar.org is non-profit and their platform itself is open source and decentralized.   Stellar was founded by Jed McCaleb in 2014. Jed McCaleb is also the founder of Mt. Gox and co-founder of Ripple, launched the network system Stellar with former lawyer Joyce Kim. Stellar is also a payment technology that aims to connect financial institutions and drastically reduce the cost and time required for cross-border transfers. In fact, both payment networks used the same protocol initially.  Distributed Exchange Through the use of its intermediary currency Lumens (XLM), a user can send any currency that they own to anyone else in a different currency.  For instance, if Joe wanted to send USD to Mary using her EUR, an offer is submitted to the distributed exchange selling USD for EUR. This submitted offer forms is known as an order book. The network will use the order book to find the best exchange rate for the transaction in-order to minimize the fee paid by a user.  This multi-currency transaction is possible because of "Anchors". Anchors are trusted entities that hold people’s deposits and can issue credit. In essence, Anchors serves as the bridge between different currencies and the Stellar network.  Lumens (XLM) Lumens are the native asset (digital currency) that exist on the Stellar network that helps to facilitate multi-currency transactions and prevent spams. For multi-currency transactions, XLM is the digital intermediary that allows for such a transaction to occur at a low cost.  In-order to prevent DoS attacks (aka spams) that would inevitably occur on the Stellar network, a small fee of 0.00001 XLM is associated with every transaction that occurs on the network. This fee is small enough so it does not significantly affect the cost of transaction, but large enough so it dissuades bad actors from spamming the network.   Prior to Protocol 12, Stellar had a built-in inflation mechanism conceived to allow account holders to collectively direct inflation-generated lumens toward projects built on Stellar.  As the network evolved and grew, it became increasingly clear that inflation wasn’t working as intended — account holders either didn’t set their inflation destination or joined inflation pools to claim the inflation themselves, and the operational costs associated with inflation payments continued to rise — and so a protocol change to disable inflation was proposed, implemented, voted on by validators, and ultimately adopted as part of a network upgrade.  The inflation operation is now deprecated. https://developers.stellar.org/docs/glossary/inflation/

Stellar Lumens

Stellar Lumens (XLM) is trending due to recent price volatility, with widespread community discussion centered on a sharp decline many characterize as a "rug pull" or "flash crash." This sentiment contrasts with ongoing network developments, including new institutional partnerships for stablecoin issuance and privacy upgrades, fueling debate about XLM's underlying value proposition for future financial infrastructure.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is currently a focal point of intense market debate, with community members divided over its near-term direction amid year-end trading dynamics. Bulls are energized by institutional accumulation and the potential for a 'new cycle theory' to drive significant price appreciation, while bears warn of an extended 'crypto winter' and continued consolidation. The prevailing discussion revolves around whether ongoing stability signals a springboard for a major rally or a precursor to further decline.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending sharply following FDA approval of NEREUS (tradipitant), marking the first new drug for motion sickness in over 40 years. The community is actively discussing the substantial potential for its off-label use in mitigating GLP-1 induced nausea and vomiting, a market opportunity seen as a major catalyst. Investors anticipate further upside, speculating on a potential buyout from a large pharmaceutical company and a short squeeze ahead of additional upcoming regulatory decisions.

Threshold is a project merged from the NuCypher and Keep networks, which strives to provide different threshold cryptography solutions in a fully decentralized manner to the web3 community. Threshold cryptography is a technology that uses cryptography to unlock greater utility and usability for digital assets without needing to trust a centralized party. Threshold cryptography distributes sensitive operations across multiple independent entities – like nodes in a network – and requires a threshold, or minimum number of those entities to cooperate for the operation to be successful.

Threshold Network Token

Threshold Network Token ($T) is drawing significant attention, driven by community excitement around its role in decentralized Bitcoin (tBTC) and its perceived potential to replace existing wrapped Bitcoin solutions. Traders are actively discussing increasing trading volume and its utility as a crucial bridge between major crypto ecosystems.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU CRYPTO is trending due to its exceptionally active and dedicated community, which is relentlessly building a permissionless brand through various real-world products like Kendu Spice and Kendu Energy. Community members are emphasizing long-term conviction, strategic accumulation, and the project's expanding IRL presence across multiple blockchain networks.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending due to recent preliminary Phase 3 data indicating an impressive 80% reduction in breast cancer recurrence rates, further bolstered by directors extending their share lock-up through September 2026. The community is actively discussing the stock's currently low valuation relative to its multi-billion dollar market opportunity and the potential for a significant short squeeze, with high borrow rates and low float intensifying the discussion around a possible partnership or acquisition. Investors are positioning for long-term growth as the de-risked breast cancer immunotherapy advances.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending on a powerful AI-driven surge, with skyrocketing demand for High Bandwidth Memory (HBM) leading to its entire 2026 HBM capacity being sold out. The community is buzzing with bullish sentiment, fueled by strong guidance and analyst upgrades, as the market re-evaluates its growth potential in the critical AI infrastructure sector despite some calls for caution due to its recent parabolic run.

Amplify ETF Trust - Amplify Junior Silver Miners ETF

Amplify Junior Silver Miners ETF

The Amplify Junior Silver Miners ETF ($SILJ) is trending as silver prices surge to historic highs, driven by robust industrial demand and concerns over fiat currency debasement. While the underlying metal sees an explosive rally, the community is actively debating the junior miners' lagging performance, with many suspecting market manipulation. Despite this, a strong bullish sentiment predicts a significant catch-up rally for $SILJ, given the widespread expectation for silver's continued ascent.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Neumora Therapeutics (NASDAQ:NMRA) Price Target Raised to $3.00 at Stifel Nicolaus

Stifel Nicolaus lifted their price objective on Neumora Therapeutics from $2.00 to $3.00 and gave the company a "hold" rating in a research note on Monday...

Neumora Therapeutics (NASDAQ:NMRA) Insider Sells 114,703 Shares

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) insider Daljit Singh Aurora sold 114,703 shares of Neumora Therapeutics stock in a transaction on Tuesday, November 11th. The stock was sold...

Insider Selling: Neumora Therapeutics (NASDAQ:NMRA) Insider Sells 114,703 Shares of Stock

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) insider Daljit Singh Aurora sold 114,703 shares of the stock in a transaction on Tuesday, November 11th. The shares were sold at an average...

HC Wainwright Has Optimistic Outlook of NMRA FY2025 Earnings

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Stock analysts at HC Wainwright raised their FY2025 earnings per share estimates for Neumora Therapeutics in a report released on Sunday...

Neumora Therapeutics (NASDAQ:NMRA) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) announced its earnings results on Thursday. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01...

<ul class="summary-bullets"><li>Neumora said that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with semaglutide.</li><li>The company now plans to initiate an early-stage clinical study for the experimental drug in the first quarter of 2026. &nbsp;</li></ul>Neumora Therapeutics, Inc. (NMRA) on Monday announced positive data from preclinical studies for its experimental weight-loss therapy NMRA-215.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/27/3174401/0/en/Neumora-Therapeutics-Announces-Class-Leading-Weight-Loss-Demonstrated-with-NMRA-215-in-Preclinical-Diet-Induced-Obesity-Model.html">said</a> that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with Semaglutide in mice with diet-induced obesity. Semaglutide is the active ingredient in Novo Nordisk’s (NVO) popular weight-loss drug Wegovy.<h2 class="st-heading-2">Plans Ahead</h2>NMRA-215 is an oral NLRP3 inhibitor in development for the treatment of obesity. It blocks the activity of the NLRP3 inflammasome, a protein complex involved in the immune response to inflammation. NLRP3-mediated neuroinflammation in the hypothalamus is linked to obesity, Neumora noted.The company now plans to initiate an early-stage clinical study for the experimental drug in the first quarter of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company jumped about 22% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NMRA">NMRA stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<blockquote>“These data demonstrate NMRA-215 drives meaningful weight loss as a monotherapy in mice, including incretin-like induction, additive weight loss in the combination setting with semaglutide, as well as the potential to enable incretin-sparing dosing regimens.” – Paul Berns, CEO, Neumora Therapeutics</blockquote>Separately, Neumora on Monday also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/27/3174424/0/en/Neumora-Therapeutics-Announces-Initiation-of-Phase-1-Clinical-Study-of-M4-Positive-Allosteric-Modulator-NMRA-898.html">announced</a> the initiation of an early-stage study of its NMRA-898 aimed at evaluating safety, tolerability, and human pharmacokinetic data of the compound for potential use in the treatment of schizophrenia and other neuropsychiatric disorders.&nbsp;NMRA stock is down by 75% this year and by about 78% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/eth-outperforms-btc-as-retail-sentiment-improves-ahead-of-fed-rate-decision/cLG030ZR3Mh">Ethereum Outperforms Bitcoin As Retail Sentiment Improves Ahead Of Fed Rate Decision, Trump-Xi Meeting This Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Neumora Therapeutics’ Experimental Drug Demonstrates Weight Loss in Preclinical Studies

Neumora said that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with Semaglutide.

Equity

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.

Current Price	$1.77
Prev Close	$1.78
Open	$1.80
Dividend Yield	0.00%
50-Day Moving Average	$2.29
Beta	1.85
Avg. Volume	1.26M
PE Ratio	-1.21

52-Week High	$3.25
52-Week Low	$0.611
Market Capitalization	$297.42M
EPS (Annual)	-$1.53
Price to Book	2.17
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

NMRA
Neumora Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NMRA News

NMRANeumora Therapeutics Inc.